Background
Given the increasing need for economic evidence to inform the resource allocation decisions of a range of decision-makers and in many jurisdictions, there is interest in the generalisability of economic evaluations, that is, the extent to which the results of a study based on measurement in a particular patient population and/or a specific context hold true for another population and/or in a different context. The context which is the primary focus of this report is the location in which the study was undertaken and/or the decision-maker for whom the study was undertaken. The focus of this report is economic evaluation as applied to health services.
Aims and objectives
The aim of the project was to review, and to develop further, the methods used to assess and to increase the generalisability of economic evaluation studies.
The specific objectives were to conduct: 1. A systematic review of methods literature on generalisability relating to economic evaluation to identify factors causing variability in costeffectiveness between locations and over time, and the extent of that variability. 2. A systematic review of methods literature on economic evaluation relating to available methods to assess variability between locations and over time. 3. A systematic review of applied economic evaluation studies undertaken alongside multilocation trials to describe how studies have assessed and reported generalisability and variability in results between locations. 4. A series of case studies involving the secondary analysis of cost-effectiveness analyses undertaken alongside multilocation trials to explore the use of multilevel modelling to assess variability in cost-effectiveness between locations. 5. A structured review of economic evaluations based on decision analytic models in the field of osteoporosis to describe how studies have made their analyses relevant to particular decision-makers/jurisdictions and assessed how results might vary across locations. 6. A case study of a decision analytic model to illustrate methods to estimate cost-effectiveness for the NHS based on data partly collected in non-UK locations.
Methods
For Objectives 1 and 2 above, methodological studies relating to economic evaluation in healthcare were searched. This included electronic searches of a range of databases, including PREMEDLINE, MEDLINE, EMBASE and EconLit, and manual searches of key journals. Similar methods were used for Objectives 3 and 5 to identify applied economic studies. The case studies (Objectives 4 and 6) involved highlighting specific features of previously published economic studies related to generalisability and locationrelated variability. In the case of Objective 4, the case-study was based on the secondary analysis of three economic studies using data from randomised trials. Dealing with variability by location in economic studies alongside multilocation trials G There have been weaknesses in some aspects of the reporting in applied cost-effectiveness studies. These may limit decision-makers' ability to judge the relevance of a study to their specific situations. G There was little use of the statistical approaches identified in the methods review to assess variability by location. G The case study demonstrated the potential value of multilevel modelling (MLM). Where clustering exists by location (e.g. centre or country), MLM can facilitate correct estimates of the uncertainty in cost-effectiveness results. G MLM also provides a means of estimating location-specific cost-effectiveness. G The use of location-specific covariates in MLM can explain some of the variation in costeffectiveness. G An important policy issue is raised by this work: the extent to which location-specific estimates of incremental net benefit are useful to decision makers.
Results

Variability in cost-
Use of decision analytic models to provide location-specific estimates of cost-effectiveness G The review of applied economic studies based on decision analytic models showed that few studies were explicit about their target decisionmaker(s)/jurisdictions.
G The studies in the review generally made more effort to ensure that their cost inputs were specific to their target jurisdiction than their effectiveness parameters. G Standard sensitivity analysis was the main way of dealing with uncertainty in the models, although few studies looked explicitly at variability between locations. G The modelling case study illustrated how effectiveness and cost data can be made location-specific. In particular, on the effectiveness side, the example showed the separation of location-specific baseline events and pooled estimates of relative treatment effect, where the latter are assumed exchangeable across locations.
Key recommendations Economic evaluation using patient-level data
G At the design stage of a study, selection of study sites should ideally focus on those that are representative of the jurisdiction(s) for which economic data are required. G There is value in collecting data on the characteristics of trial centres which could be used as covariates in regression models. G The patients included in studies should reflect the normal clinical caseload, but it is important to collect a number of patient-level variables that could be used as covariates. G Resource use data (e.g. hospital days) should be reported separately from the unit costs of those resources. G MLM should be considered as a means of assessing the degree of clustering in cost and effectiveness data within trial locations. If clustering is extensive, MLM can reflect this characteristic at the analysis stage and generate location-specific estimates of cost-effectiveness. G There remains an important role for sensitivity analysis in exploring the implications of variation in some parameters (e.g. unit costs and preference values). G Reporting more information on the centres/countries in a study can assist decisionmakers in interpreting the relevance of results to their situation.
Economic evaluation using decision analytic modelling
G Given the focus on a decision, any analysis should be clear about the specification of the decision problem and the relevant decision-maker(s) and jurisdiction(s). 
Conclusions
A large number of factors are mentioned in the literature that might be expected to generate variation in the cost-effectiveness of healthcare interventions across locations. Several papers have demonstrated differences in the volume and cost of resource use between locations, but few studies have looked at variability in outcomes.
In applied trial-based cost-effectiveness studies, few studies provide sufficient evidence for decision-makers to establish the relevance or to adjust the results of the study to their location of interest. Very few studies utilised statistical methods formally to assess the variability in results between locations. In applied economic studies based on decision models, most studies either stated their target decision-maker/jurisdiction or provided sufficient information from which this could be inferred. There was a greater tendency to ensure that cost inputs were specific to the target jurisdiction than clinical parameters.
Methods to assess generalisability and variability in economic evaluation studies have been discussed extensively in the literature relating to both trial-based and modelling studies. Regression-based methods are likely to offer a systematic approach to quantifying variability in patient-level data. In particular, MLM has the potential to facilitate estimates of cost-effectiveness which both reflect the variation in costs and outcomes between locations and also enable the consistency of cost-effectiveness estimates between locations to be assessed directly. Decision analytic models will retain an important role in adapting the results of cost-effectiveness studies between locations.
Summary of recommendations for further research
Drawing on the material in this report, it is possible to summarise some important areas for further research. As far as possible, these have been placed in priority order.
G The development of methods of evidence synthesis which model the exchangeability of data across locations and allow for the additional uncertainty in this process. These methods should relate to all parameters relevant to economic evaluation. G Assessment of alternative approaches to specifying multilevel models to the analysis of cost-effectiveness data alongside multilocation randomised trials. G Identification of a range of appropriate covariates relating to locations (e.g. hospitals) in multilevel models. G Further assessment of the role of econometric methods (e.g. selection models) for costeffectiveness analysis alongside observational datasets, and to increase the generalisability of randomised trials.
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